- Home
- Publications
- Publication Search
- Publication Details
Title
Concepts in glioma immunotherapy
Authors
Keywords
Glioblastoma, Vaccine, IDH1, EGFRvIII, Checkpoint inhibition, CIMT 2015
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 65, Issue 10, Pages 1269-1275
Publisher
Springer Nature
Online
2016-07-26
DOI
10.1007/s00262-016-1874-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid
- (2016) Christian Schläger et al. NATURE
- Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment
- (2015) Hinke F. van Thuijl et al. ACTA NEUROPATHOLOGICA
- Cancer immunotherapy: exploiting neoepitopes
- (2015) Michael Platten et al. CELL RESEARCH
- A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules
- (2015) Aleksanteri Aspelund et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Strategies to target drugs to gliomas and CNS metastases of solid tumors
- (2015) B. Milojkovic Kerklaan et al. JOURNAL OF NEUROLOGY
- Evolving treatment options for melanoma brain metastases
- (2015) Thankamma Ajithkumar et al. LANCET ONCOLOGY
- Mutant MHC class II epitopes drive therapeutic immune responses to cancer
- (2015) Sebastian Kreiter et al. NATURE
- Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients
- (2015) Duane A. Mitchell et al. NATURE
- Structural and functional features of central nervous system lymphatic vessels
- (2015) Antoine Louveau et al. NATURE
- Mutational landscape and clonal architecture in grade II and III gliomas
- (2015) Hiromichi Suzuki et al. NATURE GENETICS
- Prospects of immune checkpoint modulators in the treatment of glioblastoma
- (2015) Matthias Preusser et al. Nature Reviews Neurology
- A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study
- (2015) J. Schuster et al. NEURO-ONCOLOGY
- CD4+T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients
- (2015) Daniel Dubinski et al. NEURO-ONCOLOGY
- PD-L1 expression and prognostic impact in glioblastoma
- (2015) Edjah K. Nduom et al. NEURO-ONCOLOGY
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
- (2015) D. A. Reardon et al. Cancer Immunology Research
- Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma
- (2015) Serena Pellegatta et al. Acta Neuropathologica Communications
- Immunology of Relapse and Remission in Multiple Sclerosis
- (2014) Lawrence Steinman Annual Review of Immunology
- Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia
- (2014) M. Rajasagi et al. BLOOD
- Microenvironmental Clues for Glioma Immunotherapy
- (2014) Michael Platten et al. Current Neurology and Neuroscience Reports
- A vaccine targeting mutant IDH1 induces antitumour immunity
- (2014) Theresa Schumacher et al. NATURE
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- mRNA-based therapeutics — developing a new class of drugs
- (2014) Ugur Sahin et al. NATURE REVIEWS DRUG DISCOVERY
- Immunotherapy advances for glioblastoma
- (2014) D. A. Reardon et al. NEURO-ONCOLOGY
- Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
- (2014) Anna Sophie Berghoff et al. NEURO-ONCOLOGY
- Gliomas Promote Immunosuppression through Induction of B7-H1 Expression in Tumor-Associated Macrophages
- (2013) O. Bloch et al. CLINICAL CANCER RESEARCH
- T-helper-1-cell cytokines drive cancer into senescence
- (2013) Heidi Braumüller et al. NATURE
- Heat-shock protein peptide complex–96 vaccination for recurrent glioblastoma: a phase II, single-arm trial
- (2013) Orin Bloch et al. NEURO-ONCOLOGY
- Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma
- (2013) B. E. Johnson et al. SCIENCE
- Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities
- (2013) R. A. Cairns et al. Cancer Discovery
- Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy
- (2012) Valérie Dutoit et al. BRAIN
- Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial
- (2012) Anna Maria Di Giacomo et al. LANCET ONCOLOGY
- IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
- (2012) Sevin Turcan et al. NATURE
- Immune surveillance in the central nervous system
- (2012) Shalina S Ousman et al. NATURE NEUROSCIENCE
- Developing mRNA-vaccine technologies
- (2012) Thomas Schlake et al. RNA Biology
- Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma
- (2010) John H. Sampson et al. JOURNAL OF CLINICAL ONCOLOGY
- Monoclonal antibody specific for IDH1 R132H mutation
- (2009) David Capper et al. ACTA NEUROPATHOLOGICA
- Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas
- (2009) Christian Hartmann et al. ACTA NEUROPATHOLOGICA
- IDH1andIDH2Mutations in Gliomas
- (2009) Hai Yan et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started